@optometryadvisor.bsky.socialExtended use of digital devices is positively related with #DryEye symptoms among children and adolescents, according to research presented at the American Academy of Optometry 2026 annual meeting. @aaopt.bsky.social
Learn more: https://bit.ly/4jCImBL
@optometryadvisor.bsky.socialTreatment with lifitegrast can provide sustained symptom relief in patients with #DryEyeDisease, according to research presented at the American Academy of Optometry 2026 annual meeting. @aaopt.bsky.social
Read more: https://bit.ly/4xYSubA
@optometryadvisor.bsky.socialPatients with #DryEyeDisease (#DED) place greatest value on treatment tolerability as well as rapid and sustained symptom relief, according to research presented at the American Academy of Optometry 2026 annual meeting. @aaopt.bsky.social
Read more: https://bit.ly/4z96ocj
@oae-evcna.bsky.social👁️💧 What is the future of extracellular vesicle therapy for #dryeyedisease?
This Review discusses the principles, progress, therapeutic strategies, and challenges of #MSC-derived #EVs in ocular surface treatment.
🔗 www.oaepublish.com/articles/evc...
@profswatson.bsky.social @arvoinfo.bsky.social
@optometryadvisor.bsky.socialSemifluorinated alkane-based cyclosporine ophthalmic solution (VEVYE®, cyclosporine ophthalmic solution 0.1%) demonstrates clinically significant improvement in patient-reported #DryEyeDisease symptoms, according to research published in Clinical Ophthalmology.
Read here: https://bit.ly/4hjGQD2